Multi-omics identification and functional validation of signal regulatory protein gamma as a prognostic biomarker and immune regulator in head and neck squamous cell carcinoma
Aug 2026· Frontiers in Immunology· Vol 17· 0 citations· 44 references
Medicine
TL;DR
SIRPG is identified as an immune-related prognostic hub and context-dependent tumor-cell regulator associated with apoptosis, immune communication and spatial microenvironmental organization in HNSCC.
Abstract
Background Head and neck squamous cell carcinoma (HNSCC) comprises biologically diverse tumors, and durable responses to immune-checkpoint blockade are achieved by only a subset of patients. There remains a need for markers that connect clinical outcome with malignant-cell phenotypes and tissue-level immune organization. Methods We integrated The Cancer Genome Atlas HNSCC cohort (TCGA-HNSC), five Gene Expression Omnibus (GEO) validation cohorts, single-cell RNA sequencing, Visium spatial transcriptomics, cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq)-informed protein-potential inference, pharmacogenomic screening, genetic-risk analysis and experimental validation. A reconstructed 296-pipeline survival modelling framework was used to prioritize prognostic hub genes across validation-cohort-specific analyses. Results SIRPG was repeatedly ranked among the top ten selected genes in all five validation cohorts. At single-cell resolution, SIRPG-high tumor cells showed stronger malignant-cell features, immune-inhibitory and metabolic programs, Scissor-positive risk association, CLCA2/P53-related perturbation signals and inferred SIRPG-CD47/signal regulatory protein (SIRP) communication. Spatial analyses placed this axis within an immune-checkpoint-coupled niche, supported by Maxspin/multiview intercellular spatial modelling (MISTy) spatial coupling, communication analysis by optimal transport (COMMOT)-inferred CD47-SIRPG communication and scProTrans-inferred CD47/SIRPG protein-potential overlap. Functionally, SIRPG knockdown reduced HNSCC cell viability and increased apoptosis, whereas re-expression of short hairpin RNA (shRNA)-resistant SIRPG restored the CLCA2-BAX/BCL2 protein response. Conclusion Together, these findings identify SIRPG as an immune-related prognostic hub and context-dependent tumor-cell regulator associated with apoptosis, immune communication and spatial microenvironmental organization in HNSCC.
A five‐gene signature with strong diagnostic value and biologically meaningful prognostic relevance in EBVaGC is identified, highlighting fibroblast‐ and B‐cell‐associated microenvironmental programs in aggressive disease.
Luyu Jin, Man Jiang, Yu-Long Pan et al.· Genetics Research· 0 citations
A seven-gene immune-related prognostic signature that, combined with clinicopathological parameters, provides a robust tool for individualized survival prediction and may guide precision management in CRC patients is developed and validated.
PHLDA3 serves as a robust prognostic biomarker for HNSC and drives the formation of an immunosuppressive microenvironment, highlighting a promising therapeutic target for combined metabolic-immune strategies in HNSC.
Jingxin Guo, Zi-Feng Cui, Jinhang Wang et al.· Discover Oncology· 0 citations
An integrative single-cell eQTL-driven multi-omics framework to identify immune cell-specific causal genes and prioritize drug-repurposing candidates for HNC supports AIM1 and ANXA1 as promising biomarkers and therapeutic entry points for precision drug development.
Zhangwei Xue, Guo-Hang Shen, Gongbiao Lin et al.· Frontiers in Oncology· 0 citations
This study integrates multi-omics datasets to identify candidate biomarkers that may influence TNBC progression and modulate therapeutic response and nominate CCND2 and KIF1A as candidate biomarkers and potential therapeutic targets in TNBC.
Roberto Aguilar, Victor Wang, Shane Deng· Journal of Immunology· 0 citations
It is suggested that TRIP6 may be involved in linking microenvironmental signaling to invasive phenotypes, with potential value for prognostic stratification and therapeutic exploration.
Qiwei Cui, Xiao-Hong Gao, Xiaoqing Wu et al.· Frontiers in Cell and Develo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.